FDA perspectives on supplement use by patients on antithrombotic therapy: dietary supplement regulatory overview.
Woo
Jason J Y
JJ
Division of Dietary Supplement Programs, Office of Nutritional Products, Labeling and Dietary Supplements, Food and Drug Administration, Room 4D032, CPK1 College Park, MD 20740, USA. jason.woo@cfsan.fda.gov
D019587:Dietary Supplements / Q000592:standards*; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D004347:Drug Interactions; D004348:Drug Labeling / Q000331:legislation & jurisprudence*; D005343:Fibrinolytic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D033161:Government Regulation; D006801:Humans; D007880:Legislation, Drug; D014481:United States; D014486:United States Food and Drug Administration
D005343:Fibrinolytic Agents